The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era

The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era

Abstract Background The ALTER0203 clinical trial showed that anlotinib, a multitargeted tyrosine kinase inhibitor, had antitumor effects on advanced soft tissue sarcoma (STS) after the failure of standard chemotherapy. We aimed to evaluate the real‐world efficacy and explore prognostic factors and t...

Full description

Bibliographic Details
Main Authors: Ren‐Shu Zhang, Jie Liu, Yao‐Tiao Deng, Xin Wu, Yu Jiang
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Cancer Medicine
Subjects:
clinical management
nutrition
prognosis
soft tissue sarcoma
target therapy
tyrosine kinase inhibitors
Online Access:https://doi.org/10.1002/cam4.4613

Internet

https://doi.org/10.1002/cam4.4613

Similar Items